Civica plans to produce insulin biosimilars in both vials and prefilled pens and sell them at significantly lower prices than insulins currently on the market, according to a Jan. 31 company press release.
The company plans to set the maximum recommended price to the consumer at $30 per vial and $55 per box of five pen cartridges. Civica products are anticipated to hit the market in 2024 after FDA approval.
